Genovate Biotech, Taiwan Invest In DNA-Based Vaccine Development
This article was originally published in PharmAsia News
Executive Summary
Genovate Biotechnology and the Taiwan government have agreed to spend a combined $233,000 over the next two years to develop a DNA-based vaccine against cancer through preclinical trials.